ZA201902967B - A pharmaceutical composition for averting opioid addiction - Google Patents

A pharmaceutical composition for averting opioid addiction

Info

Publication number
ZA201902967B
ZA201902967B ZA2019/02967A ZA201902967A ZA201902967B ZA 201902967 B ZA201902967 B ZA 201902967B ZA 2019/02967 A ZA2019/02967 A ZA 2019/02967A ZA 201902967 A ZA201902967 A ZA 201902967A ZA 201902967 B ZA201902967 B ZA 201902967B
Authority
ZA
South Africa
Prior art keywords
averting
patient
pharmaceutical composition
opioid addiction
opioid
Prior art date
Application number
ZA2019/02967A
Other languages
English (en)
Inventor
Catherine Stehman¿Breen
John Davis
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ZA201902967B publication Critical patent/ZA201902967B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA2019/02967A 2016-11-29 2019-05-13 A pharmaceutical composition for averting opioid addiction ZA201902967B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
PCT/US2017/063417 WO2018102294A1 (en) 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction

Publications (1)

Publication Number Publication Date
ZA201902967B true ZA201902967B (en) 2024-10-30

Family

ID=60766150

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/02967A ZA201902967B (en) 2016-11-29 2019-05-13 A pharmaceutical composition for averting opioid addiction

Country Status (18)

Country Link
US (2) US10736961B2 (enExample)
EP (1) EP3548082B1 (enExample)
JP (1) JP7071975B2 (enExample)
KR (1) KR20190090820A (enExample)
CN (1) CN110072549A (enExample)
AU (1) AU2017366870B2 (enExample)
BR (1) BR112019010331A2 (enExample)
CA (1) CA3045116A1 (enExample)
CL (1) CL2019001385A1 (enExample)
CO (1) CO2019005247A2 (enExample)
EA (1) EA201991283A9 (enExample)
IL (1) IL266640B (enExample)
MA (2) MA46951A (enExample)
MX (1) MX2019006013A (enExample)
MY (1) MY200701A (enExample)
PH (1) PH12019501087A1 (enExample)
WO (1) WO2018102294A1 (enExample)
ZA (1) ZA201902967B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108697A1 (en) * 2018-08-10 2020-02-13 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
US20250011408A1 (en) 2021-11-19 2025-01-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023212586A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2270048B1 (en) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
MY161564A (en) * 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂

Also Published As

Publication number Publication date
CL2019001385A1 (es) 2019-07-26
US10736961B2 (en) 2020-08-11
KR20190090820A (ko) 2019-08-02
US11491222B2 (en) 2022-11-08
JP2019535716A (ja) 2019-12-12
EA201991283A9 (ru) 2019-11-27
EA201991283A1 (ru) 2019-09-30
BR112019010331A2 (pt) 2019-10-22
IL266640A (en) 2019-07-31
MA46951A (fr) 2019-10-09
AU2017366870B2 (en) 2024-09-19
CA3045116A1 (en) 2018-06-07
MA45890A1 (fr) 2020-02-28
WO2018102294A1 (en) 2018-06-07
CN110072549A (zh) 2019-07-30
AU2017366870A1 (en) 2019-06-06
JP7071975B2 (ja) 2022-05-19
PH12019501087A1 (en) 2019-08-19
US20180147280A1 (en) 2018-05-31
MX2019006013A (es) 2019-10-14
IL266640B (en) 2022-09-01
EP3548082B1 (en) 2024-05-15
CO2019005247A2 (es) 2019-05-31
MY200701A (en) 2024-01-11
EP3548082A1 (en) 2019-10-09
MA45890B2 (fr) 2022-10-31
US20210060159A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
NZ748314A (en) Anti-cmet antibody drug conjugates and methods for their use
MX2020009260A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos.
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
PH12016500349B1 (en) Anti-prlr antibodies and uses thereof
WO2014144763A3 (en) High affinity anti-gd2 antibodies
WO2017097723A3 (en) Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
NZ631543A (en) Antibodies to bradykinin b1 receptor ligands
GB201201314D0 (en) Composition
UA102775C2 (uk) Спосіб лікування болю із застосуванням анти-ngf антитіла
AU2018290532A1 (en) Immunotherapy for hepatocellular carcinoma
EP4434540A3 (en) Humanized anti-il-1r3 antibodies
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
PH12019501087A1 (en) A pharmaceutical composition for averting opioid addiction
NZ625758A (en) Method for treating breast cancer
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
HK1198135A1 (en) Prevention and treatment of pain using antibodies to lysophosphatidic acid